First AD

Second AD

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, is a consultant hematologist at King's College Hospital NHS Foundation Trust in London.

David Dingli, MD, PhD, is a professor of medicine at Mayo Clinic in Rochester, Minnesota.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss the role of C5 inhibitors in the management of paroxysmal nocturnal hemoglobinuria.

Role of C5 Inhibitors in the Management of Paroxysmal Nocturnal Hemoglobinuria

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Emerging Data and Treatment Trends in Paroxysmal Nocturnal Hemoglobinuria After EHA 2025

Mayo Clinic

Cancer Centers

Partner

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.